Pramodini Medicare IPO

The Pramodini Medicare SME IPO runs from 12 Aug 2026 to 14 Aug 2026, offered at a price band of ₹110–118 per share, and is set to list on NSE. The company is looking to raise ₹69.04 crore through the offer. Retail investors bid in lots of 1200 shares, a minimum application of ₹2,83,200.

Issue structure

The offer combines a fresh issue of ₹59.17 crore with an offer for sale (OFS) of ₹5.9 crore by existing shareholders. Money raised through the fresh issue goes to the company for its stated objects, while OFS proceeds go to the selling shareholders rather than the business.

Objects of the issue

Per the offer document, the company intends to deploy the net proceeds primarily toward funding of capital expenditure for purchase of medical equipments towards existing and proposed diagnostic centres (₹45.15 crore), alongside general corporate purposes and unidentified inorganic acquisition (₹10.76 crore). In all, 3 objects are disclosed — the full break-up is in the table above.

Financials

In FY2026, Pramodini Medicare reported revenue of ₹63.38 crore and a net profit of ₹17.38 crore. Revenue grew from ₹35.79 crore in FY2024 to ₹63.38 crore in FY2026 (+77.0%). Net worth stood at ₹53.15 crore at the end of FY2026. At the upper band, that puts the issue at roughly 11.3× FY2026 earnings (P/E), a figure worth comparing against listed peers in the sector.

Valuation

At the upper band, the issue is priced at 14.97× post-issue earnings and 3.71× book value, against a return on net worth of 32.69% and a debt-to-equity ratio of 0.34. These ratios come from the offer document and are for comparison, not a recommendation.

Peer comparison

The offer document names listed peers including Invicta Diagnostic Ltd. and Krsnaa Diagnostics Ltd., with a median peer P/E of about 13.6×. The issue's own post-issue P/E works out to 14.97×.

Promoters

The promoters of the company are <p>Chalasani Kuldeep Kumar, Chalasani Kavitha, Chalasani Durga Aashritha, Chalasani Lalithakumar, Sri Ram Medicare Pvt.Ltd.</p>. Promoter holding stands at 85.71% before the issue and comes down to 62.64% after listing.

Grey market premium (GMP)

In the unofficial grey market, Pramodini Medicare shares are quoted at a premium of ₹0 implying an expected listing around ₹118, about +0.0% over the upper band. Grey market premium is a sentiment indicator set by private dealers, not the company or the exchange — it moves quickly and is not a reliable predictor of the actual listing price.

Subscription

The Pramodini Medicare IPO was subscribed 3.87 times overall. The strongest demand came from non-institutional investors (NII) at 4.96 times, with qualified institutional buyers (QIB) at 3.66× and retail investors at 3.49×.

Listing performance

Pramodini Medicare listed on 19 Aug 2026 at ₹120, a premium of +1.7% over the issue price of ₹118.

What to weigh

When evaluating the Pramodini Medicare IPO, the data points most investors look at are the fresh-issue-versus-OFS split, the revenue and profitability trend, subscription demand across investor categories and the grey market premium. Grey market premium and subscription figures reflect short-term sentiment rather than long-term fundamentals; the figures on this page are for information only and are not investment advice.

About Pramodini Medicare

Pramodini Medicare Limited is an Indian diagnostic healthcare service provider offering technology-enabled services across radiology, clinical laboratory, and nuclear medicine. The company serves government and private hospitals, public sector undertakings (PSUs), medical colleges, private diagnostic centres, and individual patients across Tier I, II, and III cities. Its diagnostic portfolio includes MRI, CT scans, X-rays, ultrasound with colour Doppler, mammography, DEXA scans, interventional radiology, pathology, biochemistry, microbiology, immunology, haematology, PET-CT, SPECT, and nuclear therapy. The company also operates a 24×7 teleradiology centre and a central processing laboratory in Vijayawada. The company operates through four business models: Public-Private Partnerships (PPP), Private-Private Partnerships (Pvt-Pvt), strategic partnerships with PSUs, and standalone diagnostic centres. As of August 4, 2026 , it operated 16 diagnostic centres across seven states . Competitive Strengths: Strong presence across multiple states through a diversified operating model. Advanced diagnostic capabilities supported by robust IT infrastructure. Experienced management team with proven industry expertise. Consistent revenue growth and financial performance. Diversified customer base across hospitals, institutions, and individual patients.